Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Equity Bottom-Up

<p>We took another look at the design of the on-going phase 2/3 clinical trial for <a href="https://www.smartkarma.com/entities/10499" target="_blank" data-smartkarma-citation="entities:10499:1">Medgenics Inc (MDGN US)</a> NFC-1, to treat adolescents with attention deficit hyperactivity disorder, ADHD with mGluR+ (metabotropic glutamate receptor positive) mutations. ADHD is about $10 billion per year market in the US. mGluR+ tier 1 and 2 mutations may be seen in 20% of all ADHD patients. Treatment for ADHD with these mutations may represent about $2 to 3 billion per year revenue opportunity in the US alone…</p>

We took another look at the design of the on-going phase 2/3 clinical trial for Medgenics Inc (MDGN US) NFC-1, to treat adolescents with attention deficit hyperactivity disorder, ADHD with mGluR+ (metabotropic glutamate receptor positive) mutations. ADHD is about $10 billion per year market in the US. mGluR+ tier 1 and 2 mutations may be seen in 20% of all ADHD patients. Treatment for ADHD with these mutations may represent about $2 to 3 billion per year revenue opportunity in the US alone…

Actionable Idea: Medgenics: Upcoming Catalyst, Recent Insider Buying, Huge Potential Market in ADHD.

United States

Alaunos Therapeutics Inc. operates as a clinical stage cellular immuno-oncology company. The Company focuses on the treatment of solid tumors through adoptive TCR-T cell therapy. Alaunos Therapeutics serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alaunos Therapeutics (TCRT US)

Actionable Idea: Medgenics: Upcoming Catalyst, Recent Insider Buying, Huge Potential Market in ADHD.

We took another look at the design of the on-going phase 2/3 clinical trial for Medgenics Inc (MDGN US) NFC-1, to treat adolescents with attention...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)